背景:尽管目前食管癌(EC)的常规治疗策略已被证明是有效的,它们通常伴随着严重的不良事件.因此,仍有必要继续探索新的EC治疗策略,以改善患者的临床结局.
目的:阐明沙利度胺(THAL)和S-1(替加氟,gimeracil,和oeracil钾胶囊)治疗EC及其对血清肿瘤标志物(STMs)的影响。
方法:首先,选取2019年11月至2022年11月在淄博市148医院接受治疗的62例EC患者,根据接受治疗情况分组。其中,30例使用顺铂和5-氟尿嘧啶进行CCRT的患者被分配到对照组(Con),32例接受THAL和S-1CCRT的患者被分配到研究组(Res)。第二,在疗效方面进行了组间比较,药物毒性的发生率,STMs[碳水化合物抗原125(CA125)和巨噬细胞炎性蛋白-3α(MIP-3α)],血管生成相关指标[血管内皮生长因子(VEGF);VEGF受体-1(VEGFR-1);碱性成纤维细胞生长因子(bFGF);血管生成素-2(Ang-2)],和生活质量(QoL)[QoL核心30(QLQ-C30)]治疗一个月后。
结果:分析显示两个患者队列之间的总体反应率和疾病控制率没有统计学差异;但是,Res中I-II级骨髓抑制和胃肠道反应的发生率显着低于Conn。此外,治疗后CA125,MIP-3α,VEGF,VEGFR-1,bFGF,与治疗前水平和相应的治疗后水平相比,Res中的Ang-2水平明显较低。此外,从物理维度来看,QLQ-C30得分有更明显的改善,角色,情感,和社会功能是在研究中确定的。
结论:上述结果证明了THAL+S-1CCRT对EC的有效性,这有助于轻微的副作用和显著降低CA125,MIP-3α,VEGF,VEGFR-1,bFGF,Ang-2水平,从而抑制肿瘤的恶性进展并提高患者的生活质量。
BACKGROUND: Although the current conventional treatment strategies for esophageal carcinoma (EC) have been proven effective, they are often accompanied by serious adverse events. Therefore, it is still necessary to continue to explore new therapeutic strategies for EC to improve the clinical outcome of patients.
OBJECTIVE: To elucidate the clinical efficacy of concurrent chemoradiotherapy (CCRT) with thalidomide (THAL) and S-1 (tegafur, gimeracil, and oteracil potassium capsules) in the treatment of EC as well as its influence on serum tumor markers (STMs).
METHODS: First, 62 patients with EC treated at the Zibo 148 Hospital between November 2019 and November 2022 were selected and grouped according to the received treatment. Among these, 30 patients undergoing CCRT with cis-platinum and 5-fluorouracil were assigned to the control group (Con), and 32 patients receiving CCRT with THAL and S-1 were assigned to the research group (Res). Second, inter-group comparisons were carried out with respect to curative efficacy, incidence of drug toxicities, STMs [carbohydrate antigen 125 (CA125) and macrophage inflammatory protein-3α (MIP-3α)], angiogenesis-related indicators [vascular endothelial growth factor (VEGF); VEGF receptor-1 (VEGFR-1); basic fibroblast growth factor (bFGF); angiogenin-2 (Ang-2)], and quality of life (QoL) [QoL core 30 (QLQ-C30)] after one month of treatment.
RESULTS: The analysis showed no statistical difference in the overall response rate and disease control rate between the two patient cohorts; however, the incidences of grade I-II myelosuppression and gastrointestinal reactions were significantly lower in the Res than in the Con. Besides, the post-treatment CA125, MIP-3α, VEGF, VEGFR-1, bFGF, and Ang-2 Levels in the Res were markedly lower compared with the pre-treatment levels and the corresponding post-treatment levels in the Con. Furthermore, more evident improvements in QLQ-C30 scores from the dimensions of physical, role, emotional, and social functions were determined in the Res.
CONCLUSIONS: The above results demonstrate the effectiveness of THAL + S-1 CCRT for EC, which contributes to mild side effects and significant reduction of CA125, MIP-3α, VEGF, VEGFR-1, bFGF, and Ang-2 Levels, thus inhibiting tumors from malignant progression and enhancing patients\' QoL.